On the stock market since 2026, it operates in the world of health and science. It has 65 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
Debt is low and cash is strong; the finances stand solid.
The price isn’t cheap next to earnings — that’s why this grade sits in the middle.
Clearly below the class average.
The price is looking for direction — no strong breakout, no collapse.
Growth: Sales growth trails the sector average.
Business Quality: Profit power and business quality trail similar companies in the sector.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Profit per Sale: The profit kept from each sale is thin.
The stock trades below its recent peak — about 12% off the top. A pullback, not a collapse.
There is $107.4M in the vault; even if every debt were paid off, $105.9M would remain.
The average analyst price target is $50.50 — 93% above today’s price.
A loss of $39.9M against $0 in annual sales.
The growth engine is running at low revs right now. Report-card grade: 37/100.
Measured against its sector, the quality of the business sits below the class average. Report-card grade: 45/100.
On our five-subject report card, SGP sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: SGP is a high-risk stock — not yet profitable, and its future rides on its product catching on.
Analysts’ average target sits above today’s price, yet the valuation grade (51/100) says the stock isn’t cheap.